Top Markets
Coin of the day
Catalent, Inc. Catalent, Inc.

Catalent, Inc.

CTLT
株式のランク #1925
Catalent, Inc., operating globally through its various subsidiaries,... Catalent, Inc., operating globally through its various subsidiaries, specializes in the development and production of comprehensive solutions for a wide array of products, including pharmaceutical drugs, protein-based biologics, advanced cell and gene therapies, and consumer health items. The company's operations are strategically divided into four key segments: Biologics; Softgel and Oral Technologies; Oral and Specialty Delivery; and Clinical Supply Services. The Softgel and Oral Technologies division focuses on the formulation, development, and manufacturing of soft capsules. These are utilized in a diverse range of client products, such as prescription medications, over-the-counter drugs, nutritional supplements, unit-dose cosmetics, and medicinal preparations for animal health. Within the Biologics segment, Catalent undertakes the creation of biologic cell lines, develops and manufactures both cell therapy and viral-based gene therapy, and handles the formulation and production of parenteral dose forms, including vials, prefilled syringes, and cartridges. This segment also provides essential analytical development and testing capabilities. The Oral and Specialty Delivery segment offers extensive formulation, development, and manufacturing expertise across various technologies. It provides integrated downstream solutions spanning clinical development and commercial supply. This segment also features a dedicated oral delivery solutions platform, encompassing preclinical screening, formulation, analytical development, and current good manufacturing practices (cGMP) services. Finally, the Clinical Supply Services segment delivers vital support for drug and biologic clinical trials. Its services include manufacturing, specialized packaging, secure storage, efficient distribution, and comprehensive inventory management. This segment also offers "FastChain," a demand-led clinical supply service. Catalent serves a broad client base, including pharmaceutical, biotechnology, and consumer health organizations, alongside companies in other healthcare sectors like animal health and medical devices, and even the cosmetics industry. The company was founded in 2007 and maintains its headquarters in Somerset, New Jersey.
株価
$63.48
最終同期: 2024-12-17
時価総額
$11.52B
変化(1日)
0.00%
変化(1年)
0.00%
US
取引 Catalent, Inc. (CTLT)

カテゴリー

Catalent, Inc.(CTLT)のP/E比率
August 2026 時点のP/E比率 TTM -11.02
Catalent, Inc. の最新の財務報告および株価によると、現在の P/E (TTM) は -11.02 です。2023 年末時点での P/E は -33.83 でした。
Catalent, Inc. の P/E 比率の履歴(2011 〜 2026)
各年末のP/E比率
P/E比率 変化
2026 (TTM) -11.02 13.03%
2024 -9.75 -71.19%
2023 -33.83 -189.39%
2022 37.84 21.87%
2021 31.05 -51.08%
2020 63.47 10.50%
2019 57.44 -12.63%
2018 65.74 64.52%
2017 39.96 55.29%
2016 25.73 55.29%
2015 16.57 -88.55%
2014 144.74 -388.22%
2013 -50.22 -47.75%
2012 -96.12 121.31%
2011 -43.43 0.00%
類似企業や競合他社のP/E比率
P/E比率の読み方

株価収益率(P/E Ratio)は、企業の株価と1株あたり利益の関係を示します。
低いが正のP/Eは、現在の評価額に対して高い利益を上げている企業を示し、割安と見なされる可能性があります。高い負の(0に近い)P/Eは、損失が大きいことを示します。

P/Eが30を超えるか、負である企業は一般に「成長株」と見なされ、投資家は将来的な成長または黒字化を期待しています。

10未満の正のP/Eを持つ企業は一般に「割安株」と見なされ、既に収益性が高いが成長の余地は小さいと見なされます。